Anne Hansen Ree

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway
    Int J Cancer 97:28-33. 2002
  2. ncbi Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, Oslo
    Anticancer Res 22:1949-57. 2002
  3. ncbi Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Oncogene 22:8952-5. 2003
  4. ncbi Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Anticancer Res 24:555-62. 2004
  5. ncbi Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
    Sigurd Folkvord
    Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway
    Int J Radiat Oncol Biol Phys 78:555-62. 2010
  6. ncbi Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
    Kjersti Flatmark
    Department of Tumor Biology, Rikshospitalet Radiumhospitalet Medical Center, University of Oslo, 0310 Oslo, Norway
    Radiat Oncol 1:25. 2006
  7. ncbi Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
    Marie Grøn Saelen
    Department of Tumor Biology, Oslo University Hospital Radiumhospitalet, Oslo, Norway
    Angiogenesis 14:481-9. 2011
  8. ncbi Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
    Ase Bratland
    Department of Tumor Biology, Oslo University Hospital, Montebello, 0310, Oslo, Norway
    Clin Exp Metastasis 26:485-96. 2009
  9. ncbi Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
    Sigurd Folkvord
    Department of Tumor Biology, Institute for Cancer Research, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway
    Int J Radiat Oncol Biol Phys 74:546-52. 2009
  10. ncbi Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
    Ragnhild V Nome
    Department of Tumor Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Mol Cancer Ther 4:1231-8. 2005

Collaborators

Detail Information

Publications24

  1. ncbi Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway
    Int J Cancer 97:28-33. 2002
    ..Our study provides detailed information on how to combine an immunomagnetic selection procedure and differential display analysis to reveal gene expression profiles that may characterize BM micrometastatic cells...
  2. ncbi Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, Oslo
    Anticancer Res 22:1949-57. 2002
    ..The observations in this study strengthen the assumption that com1 may be involved in the tumor cell response to regulatory signals upon metastasis formation...
  3. ncbi Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Oncogene 22:8952-5. 2003
    ..Our observations provide new information about the diversity of regulatory mechanisms governed by BRCA1 in DNA damage checkpoint control...
  4. ncbi Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Anticancer Res 24:555-62. 2004
    ....
  5. ncbi Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
    Sigurd Folkvord
    Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway
    Int J Radiat Oncol Biol Phys 78:555-62. 2010
    ..This study aimed to determine whether tumor kinase activity profiles might predict tumor response to preoperative CRT in locally advanced rectal cancer (LARC)...
  6. ncbi Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
    Kjersti Flatmark
    Department of Tumor Biology, Rikshospitalet Radiumhospitalet Medical Center, University of Oslo, 0310 Oslo, Norway
    Radiat Oncol 1:25. 2006
    ....
  7. ncbi Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
    Marie Grøn Saelen
    Department of Tumor Biology, Oslo University Hospital Radiumhospitalet, Oslo, Norway
    Angiogenesis 14:481-9. 2011
    ..In this cohort of rectal cancer patients, tumor phenotypes defined by a subset of tyrosine kinase activities correlating with weak ex vivo inhibition by sunitinib, was associated with early systemic dissemination...
  8. ncbi Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
    Ase Bratland
    Department of Tumor Biology, Oslo University Hospital, Montebello, 0310, Oslo, Norway
    Clin Exp Metastasis 26:485-96. 2009
    ....
  9. ncbi Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
    Sigurd Folkvord
    Department of Tumor Biology, Institute for Cancer Research, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway
    Int J Radiat Oncol Biol Phys 74:546-52. 2009
    ..The aim of the present study was to evaluate the radiosensitizing properties of suberoylanilide hydroxamic acid (SAHA) and the possible requirement of histone hyperacetylation at radiation exposure...
  10. ncbi Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
    Ragnhild V Nome
    Department of Tumor Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Mol Cancer Ther 4:1231-8. 2005
    ..Among molecular cell cycle-targeted drugs currently in the pipeline for testing in early-phase clinical trials, HDAC inhibitors may have therapeutic potential as radiosensitizers...
  11. ncbi DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Anticancer Res 26:1909-16. 2006
    ..Moreover, the targeting of cell cycle checkpoint responses may modify the cytotoxic effect of DNA damage...
  12. ncbi Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
    Anne Hansen Ree
    Department of Tumor Biology, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Radiother Oncol 72:305-10. 2004
    ....
  13. ncbi Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
    Anne Hansen Ree
    Department of Tumour Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Lancet Oncol 11:459-64. 2010
    ..Histone deacetylase (HDAC) inhibitors have shown radiosensitising activity in preclinical tumour models. This phase 1 study assessed the use of vorinostat combined with pelvic palliative radiotherapy for gastrointestinal carcinoma...
  14. ncbi Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
    Sigurd Folkvord
    Department of Tumor Biology, Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    Radiother Oncol 86:428-34. 2008
    ..However, only limited preclinical data are available on oxaliplatin as radiosensitizer in colorectal carcinoma...
  15. ncbi Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions
    Kathrine Røe
    Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Neoplasia 12:818-25. 2010
    ....
  16. ncbi Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
    Anne Hansen Ree
    Department of Oncology, Akershus University Hospital, Lørenskog, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway
    PLoS ONE 7:e50806. 2012
    ....
  17. ncbi Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
    Marie Grøn Saelen
    Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, P, O, Box 4953, Nydalen, 0424, Oslo, Norway
    Radiat Oncol 7:165. 2012
    ..abstract:..
  18. ncbi MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
    Therese Seierstad
    Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    Radiother Oncol 93:279-84. 2009
    ..To evaluate a simultaneous integrated boost (SIB) strategy in preoperative radiotherapy of rectal cancer patients following neoadjuvant chemotherapy using pre- and post-chemotherapy tumor volumes assessed by MRI...
  19. ncbi The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
    Ase Bratland
    Department of Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway
    Clin Exp Metastasis 20:541-7. 2003
    ..Hormonal control of TIMP-2 expression in prostate carcinoma cells has not been previously reported, but whether such regulation has any functional role in the development of osteoblastic metastases in prostate cancer is still unclear...
  20. ncbi Preoperative radiotherapy in rectal signet-ring cell carcinoma - magnetic resonance imaging and treatment outcome: Report of six cases
    Ase Bratland
    Division of Cancer Medicine and Radiotherapy, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, Oslo, Norway
    Acta Oncol 49:42-9. 2010
    ..The recognition of MRI features that correlate with the radiation response might ultimately be used to select patients for tailored treatment and, in addition, avoid potentially toxic therapy in non-responding patients...
  21. ncbi Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
    Siri Lagethon Heck
    Department of Radiology, Division of Diagnostics and Technology, Akershus University Hospital and University of Oslo, Oslo, Norway
    Cardiology 123:240-7. 2012
    ..Conclusion: PRADA may provide new information on the prophylactic effect of ARB and beta-blockers in patients with early breast cancer regarding the risk of developing cardiac dysfunction from adjuvant cancer treatment...
  22. ncbi [Cell cycle-targeted therapy]
    Anne Hansen Ree
    Onkologisk avdeling, Det Norske Radiumhospital, 0310 Oslo
    Tidsskr Nor Laegeforen 124:2479-82. 2004
    ..The cell cycle checkpoints may also be biological targets for new therapeutic strategies in cancer intervention...
  23. ncbi [Molecular targeted therapy in colorectal cancer]
    Anne Hansen Ree
    Akershus universitetssykehus, Universitetet i Oslo og Tumorbiologisk avdeling, Rikshospitalet, 0310 Oslo
    Tidsskr Nor Laegeforen 128:190-3. 2008
    ..Molecular targeting agents inhibit cellular signalling mechanisms that govern tumour cell proliferation and survival...
  24. ncbi HDAC2 deficiency and histone acetylation
    Anne Hansen Ree
    Nat Genet 40:812-3; author reply 813. 2008